229 related articles for article (PubMed ID: 34347394)
1. Molecular testing for acute myeloid leukemia.
Qin D
Cancer Biol Med; 2021 Aug; 19(1):4-13. PubMed ID: 34347394
[TBL] [Abstract][Full Text] [Related]
2.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Turk J Haematol; 2018 Mar; 35(1):49-53. PubMed ID: 29129825
[TBL] [Abstract][Full Text] [Related]
3. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
[TBL] [Abstract][Full Text] [Related]
5. Multiplex fusion gene testing in pediatric acute myeloid leukemia.
Iijima-Yamashita Y; Matsuo H; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Takahashi H; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):47-51. PubMed ID: 29105243
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results.
Kahraman CY; Sincan G; Tatar A
Eurasian J Med; 2022 Jun; 54(2):181-185. PubMed ID: 35703527
[TBL] [Abstract][Full Text] [Related]
7. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment.
Peroni E; Randi ML; Rosato A; Cagnin S
J Exp Clin Cancer Res; 2023 Oct; 42(1):259. PubMed ID: 37803464
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
10. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients.
Prieto-Conde MI; Corchete LA; García-Álvarez M; Jiménez C; Medina A; Balanzategui A; Hernández-Ruano M; Maldonado R; Sarasquete ME; Alcoceba M; Puig N; González-Calle V; García-Sanz R; Gutiérrez NC; González-Díaz M; Chillón MC
J Mol Diagn; 2020 Jan; 22(1):60-71. PubMed ID: 31605801
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.
Kansal R
Cancer Biol Med; 2016 Mar; 13(1):41-54. PubMed ID: 27144061
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.
Mack EKM; Marquardt A; Langer D; Ross P; Ultsch A; Kiehl MG; Mack HID; Haferlach T; Neubauer A; Brendel C
Haematologica; 2019 Feb; 104(2):277-287. PubMed ID: 30190345
[TBL] [Abstract][Full Text] [Related]
13. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples.
Altimari A; de Biase D; De Maglio G; Gruppioni E; Capizzi E; Degiovanni A; D'Errico A; Pession A; Pizzolitto S; Fiorentino M; Tallini G
Onco Targets Ther; 2013; 6():1057-64. PubMed ID: 23950653
[TBL] [Abstract][Full Text] [Related]
14. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.
Rosli AA; Azlan A; Rajasegaran Y; Mot YY; Heidenreich O; Yusoff NM; Moses EJ
Clin Exp Med; 2023 Aug; 23(4):1137-1159. PubMed ID: 36229751
[TBL] [Abstract][Full Text] [Related]
16. Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.
Wertheim GB; Hexner E; Bagg A
Mol Diagn Ther; 2012 Dec; 16(6):357-69. PubMed ID: 23184342
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
18. Transforming Acute Myeloid Leukemia Treatment Through Next-Generation Sequencing: A Single-Center Experience.
Devarkonda V; Akabane H
Cureus; 2023 Sep; 15(9):e45917. PubMed ID: 37885525
[TBL] [Abstract][Full Text] [Related]
19. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
20. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
